BMI OrganBank
- Company typePrivate
- Founded2015
- HeadquartersWinston Salem, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BMI OrganBank does
BMI OrganBank (legal entity: BioMedInnovations LLC, founded 2015 in North Carolina, rebranded to BMI OrganBank in 2022) is a privately-held medical device company developing room temperature machine perfusion (RTMP) technology for organ and tissue preservation prior to transplantation. The company's flagship OrganBank Kidney/Transport platform is a portable, self-contained device that delivers controlled pulsatile perfusion using an oxygenated acellular perfusate (DEVOL Solution) in a temperature-regulated environment (4–37°C), monitoring perfusion flow, temperature, pressure, and vascular resistance in real time. The system is designed to preserve kidneys for up to 72 hours in vitro and is adaptable across kidney, liver, lungs, intestine, brain, and vascularized composite allografts, with FDA Breakthrough Device Designation secured in August 2025.
The integrated platform also includes the OrganBank Monitor mobile app (real-time tracking and assessment metrics), OrganIQ (AI-based transplant outcomes prediction), OrganBank Nest (patient-facing experience module), and OrganBank Lab (pharmacodynamic research services). The underlying CaVESWave technology is patented, and the company holds an exclusive license to Duke University's DEVOL perfusion technology. The company has completed over 100 preclinical procedures across multiple organ types.
BMI OrganBank operates an enterprise field-sales go-to-market targeting transplant centers, organ procurement organizations (OPOs), and donor hospitals, with named anchor partners including Atrium Health's Division of Abdominal Transplant, LifeShare Carolinas, Dedicated Staffing Solutions, Duke DEVOL, Wake Forest Institute for Regenerative Medicine, and UNC Kidney Center. Revenue today is essentially preclinical and research-services-based; the company is conducting a seed funding round and has been primarily capitalized through non-dilutive NIH ($3.5M SBIR), NSF ($2.5M), NCBiotech, and Duquesne grants, plus angel/seed investments from the National Kidney Foundation Innovation Fund, 1435 Capital, Mid Atlantic Bio Angels, Sonnerie VC, and TCA Venture Group.
BMI OrganBank firmographics
Firmographics- Name
- BMI OrganBank
- Legal name
- BioMedInnovations LLC
- Website
- https://bmiorganbank.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
BMI OrganBank industry classification
Industry- Product category
- Organ Preservation Medical Devices
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Home Dialysis Equipment & Remote Monitoring (HLAHAKAG)
Keywords
Where BMI OrganBank is headquartered
LocationHeadquarters
- HQ city
- Winston Salem
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
BMI OrganBank business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- Medical Device Sales: Sale of organ preservation systems including OrganBank Kidney transport device, DEVOL Solution perfusate, and related monitoring systems to transplant centers, OPOs, and donor hospitals.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
BMI OrganBank product offering
Product offeringCore offering
BMI OrganBank develops and sells an integrated organ preservation platform centered on its Room Temperature Machine Perfusion (RTMP) technology. The flagship OrganBank Kidney transport device uses CaVESWave technology with oxygenated acellular perfusate (DEVOL Solution) to preserve and assess kidneys ex vivo for up to 72 hours, enabling functional viability assessment before transplant. The system is complemented by a mobile monitoring app (OrganBank Monitor), AI-based outcomes prediction (OrganIQ), and a patient-facing platform (OrganBank Nest). The technology is sold to transplant centers, organ procurement organizations, and donor hospitals to address the organ discard problem (25% of donated kidneys not transplanted) and extend transport distances beyond current 500-mile limitations.
Product overview
BMI OrganBank offers an integrated organ preservation and assessment platform comprising multiple products: the OrganBank Kidney/Transport device (FDA Breakthrough Device-designated portable perfusion system), DEVOL Solution (acellular perfusate), OrganBank Monitor (mobile tracking app), OrganIQ (AI-based outcomes prediction), and OrganBank Nest (patient experience module). The system uses room temperature machine perfusion (RTMP) to preserve and assess organs ex vivo, enabling functional assessment before transplant and extended preservation times without requiring blood. The platform also includes OrganBank Lab for pharmacodynamic research services.
Differentiator
Problem solved
Functional benefit
Brands
- OrganBank Kidney: Practical kidney assessment and preservation device, suitable for ground and air transport.
- OrganBank Transport
- DEVOL Solution
- OrganBank Monitor
- OrganIQ
- OrganBank Nest
- OrganBank Lab
Products and services
- OrganBank Kidney A portable, self-contained organ preservation and transport system designed for kidney preservation during transit, delivering controlled pulsatile perfusion using an oxygenated acellular solution in a temperature-regulated environment with real-time monitoring of perfusion flow, temperature, pressure, and vascular resistance. Suitable for ground and air transport.
- OrganBank Transport Self-contained organ transport system adaptable for multiple organs including kidney, liver, lungs, intestine, brain, and vascularized composite allografts (VCA). Features temperature control ramping from 4 to 37 degrees, auto-adjusted perfusion flow with customizable waveforms, and removable aseptic cassettes for quick organ loading and unloading.
- DEVOL Solution Acellular (blood-free) perfusate solution that mimics the oncotic pressure, osmotic pressure, and acid-base balance of human plasma while providing critical electrolytes including sodium, calcium, and potassium. Consumable used with OrganBank Kidney/Transport devices.
- OrganIQ AI-based transplant outcomes prediction tool that utilizes BMI's unique clinical study data set, paired with the OrganBank Monitor mobile app to support clinical decision-making for organ transplantation.
- OrganBank Lab Pharmacodynamic research platform offering ex vivo organ perfusion research capabilities, supporting pre-clinical studies and development of novel preservation and assessment technologies.
Quantifiable outcome
- Reduced delayed graft function in preclinical porcine model compared to traditional hypothermic preservation
- +3 more outcomes
Companies that use BMI OrganBank
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
BMI OrganBank technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature8 records
BMI OrganBank partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and minor.
- Dedicated Staffing Solutions (DSS)coreStrategic partnership combining BMI OrganBank's preservation technology with DSS's specialized clinical staffing expertise to support donor hospitals, organ procurement organizations, and transplant centers. DSS, formerly Donor Staff Support, reported highest-volume year in 2025 and expects continued expansion in 2026.
- Faron PharmaceuticalsminorCollaboration leveraging cutting-edge therapeutics for vascular protection alongside BMI organ preservation technologies in limb preservation research.
- Atrium Health Division of Abdominal Transplant, Carolinas Medical CentercorePartnership to launch nation's first Organ Banking technology. Includes early access to BMI technologies, collaboration on product design, clinical studies, clinical integration pilots, and undisclosed capital arrangement. DAT Atrium is part of nation's fifth largest Integrated Delivery Network performing nearly 200 organ transplants annually.
- LifeShare CarolinascorePartnership with nation's leading Organ Procurement Organization to develop and launch Organ Banking technology. LifeShare Carolinas serves 3+ million people across southwestern North Carolina and ranks in top 25% of OPOs nationally.
- Duke University / Ex Vivo Organ Laboratory (DEVOL)coreLong-standing research partnership. In 2020 BMI began collaborating with DEVOL to develop perfusion tools. In 2022 BMI exclusively licensed assets from Duke collaboration. DEVOL generates preclinical data and supports clinical development.
- Wake Forest Institute for Regenerative Medicine (WFIRM)coreIn 2021 BMI became first tenant at Innovation Accelerator within WFIRM. WFIRM provides state-of-the-art biomanufacturing equipment, industry expertise, and talent. Anthony Atala serves as WFIRM director.
- Atrium Health Wake Forest BaptistcoreDivision of Abdominal Transplant partnership for clinical integration and technology adoption. Partnership leverages Atrium Health's position as one of nation's largest health systems.
- UNC Kidney CentercoreStrategic collaboration with UNC Kidney Center for kidney transplant research and technology development. Co-directed by Dr. Prabir Roy-Chaudhury.
- Duquesne University School of Pharmacycore$1.5 million grant partnership led by Dr. Jelena M. Janjic to develop novel preservation strategies for human limbs using nanoparticle oxygen carriers alongside BMI technology.
- Department of Defense / Armed Forces Institute for Regenerative Medicine (AFIRM)corePartnership with DOD AFIRM for regenerative medicine research. Focus on military applications including traumatic injury treatments and vascularized composite allotransplantation.
- RegenMed Development Organization (ReMDO)coreNon-profit dedicated to promoting regenerative medicine. Runs Innovation Accelerator where BMI is tenant. Provides access to ReMDO Test Bed for device testing and commercial product development.
- Lawrence Livermore National Laboratory (LLNL)minorStrategic collaboration for advanced research capabilities in organ preservation technology.
- Cystic Fibrosis FoundationminorStrategic collaboration for research applications of perfusion technology in lung preservation.
- Kidney Health InitiativeminorPublic-private partnership between American Society of Nephrology and FDA. BMI collaboration focused on advancing kidney health solutions.
- Valley BankminorCo-presenter of NJx Venture Summit where BMI OrganBank was highlighted as presenting company for angel investment.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
BMI OrganBank competitors and assessment
Company assessmentDirect peers
- TransMedics Group: TransMedics develops the Organ Care System (OCS), a portable normothermic perfusion platform for heart, lung, and liver preservation—directly competing with BMI OrganBank's RTMP platform in the organ preservation and transport category for transplant centers and OPOs.
- XVIVO Perfusion: XVIVO Perfusion provides machine perfusion and cold storage solutions for liver, kidney, heart, and lung transplantation. Directly competes with BMI OrganBank in the ex vivo organ preservation device category serving transplant centers.
- OrganOx: OrganOx developed metra (normothermic machine perfusion for liver preservation), a direct competitive platform to BMI's OrganBank multi-organ approach. Both target transplant center adoption for ex vivo organ assessment and extended preservation.
- Paragonix Technologies: Paragonix manufactures SherpaPak organ transport systems for heart, lung, and kidney preservation. Directly comparable to BMI OrganBank's OrganBank Transport product in serving OPOs and transplant centers with portable preservation devices.
- Organ Recovery Systems: Organ Recovery Systems produces the LifePort Kidney Transporter, a hypothermic machine perfusion device widely deployed at transplant centers. A direct competitor to BMI's OrganBank Kidney, particularly in the kidney preservation device category.
- Bridge to Life: Bridge to Life supplies organ preservation solutions including static cold storage and machine perfusion products for liver, kidney, and pancreas transplantation. Directly comparable as a competing preservation technology provider for transplant programs.
- Institut Georges Lopez (IGL): IGL manufactures preservation solutions (Celsior, SCOT, IGL-1) used in organ transplantation static cold storage and machine perfusion protocols. Directly competes with BMI's DEVOL Solution perfusate in the organ preservation consumables category.
- Waters Medical Systems: Waters Medical Systems manufactures the RM3 (Belzer) hypothermic perfusion machines and preservation solutions for kidney transplantation. Directly comparable as a kidney preservation device competitor to BMI's OrganBank Kidney platform.
- Preservation Solutions: Preservation Solutions develops static cold storage and perfusate products (e.g., Belzer UW, Custodiol HTK) for organ preservation. Comparable to BMI's DEVOL Solution as an organ preservation consumable provider, though focused on static cold storage rather than machine perfusion.
Broad incumbents
- Terumo: Terumo BCT is a broad incumbent in blood and cell therapy technologies with peripheral organ preservation offerings. Comparable as a large medtech player adjacent to organ preservation, with broader portfolio beyond BMI's specialized RTMP focus.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BMI OrganBank social profiles
Digital presenceBMI OrganBank financial estimates
Financial estimateRevenue estimate
Valuation estimate
BMI OrganBank leadership team
Management profileNumber of profiles
Profiles12 records
BMI OrganBank funding detail
Funding detailFunding overview
Funding rounds4 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BMI OrganBank M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BMI OrganBank
What does BMI OrganBank do?
BMI OrganBank develops and sells an integrated organ preservation platform centered on its Room Temperature Machine Perfusion (RTMP) technology. The flagship OrganBank Kidney transport device uses CaVESWave technology with oxygenated acellular perfusate (DEVOL Solution) to preserve and assess kidneys ex vivo for up to 72 hours, enabling functional viability assessment before transplant. The system is complemented by a mobile monitoring app (OrganBank Monitor), AI-based outcomes prediction (OrganIQ), and a patient-facing platform (OrganBank Nest). The technology is sold to transplant centers, organ procurement organizations, and donor hospitals to address the organ discard problem (25% of donated kidneys not transplanted) and extend transport distances beyond current 500-mile limitations.
Is BMI OrganBank a public or private company?
BMI OrganBank is a private company. It is classified as venture growth investor backed and is currently operating.
When was BMI OrganBank founded?
BMI OrganBank was founded in 2015. It employs 11 to 50 people.
Where is BMI OrganBank based?
BMI OrganBank is headquartered in Winston Salem, United States, in the North America region.
How does BMI OrganBank make money?
One revenue line is on record: medical Device Sales.
Who are BMI OrganBank's main competitors?
Direct peers on record are TransMedics Group, XVIVO Perfusion, OrganOx, Paragonix Technologies, Organ Recovery Systems, Bridge to Life, Institut Georges Lopez (IGL), Waters Medical Systems and Preservation Solutions. Terumo is listed as a broad incumbent.
Does BMI OrganBank have an API?
No public API is recorded for BMI OrganBank.
What industry is BMI OrganBank in?
BMI OrganBank's product category is Organ Preservation Medical Devices. Its primary akta.pro industry code is HLAHAKAG, Home Dialysis Equipment & Remote Monitoring. Its SIC code is 3841.